Lenvatinib Dose Reduction: — Why Most Patients Need One

The evidence does not support that concern. In the SELECT trial, the majority of patients required dose reductions and the trial still demonstrated a clear slowing of disease progression. A dose reduction changes the amount of drug in your body, but treatment continues to be active. Your oncologist monitors for signs of progression independently of dose decisions, so any change in how your disease is behaving will be picked up through scans and tests, not assumed from the dose level.

Most side effects begin to ease within a few weeks of a dose reduction, though the timing varies by symptom. Hand-foot skin reaction and diarrhoea often settle relatively quickly. Blood pressure can take longer to normalise even after reducing the dose, because it sometimes reflects cumulative effects rather than just the most recent days of treatment. Your team will monitor you during this period rather than waiting for your next scheduled appointment.

For differentiated thyroid cancer, the lowest pre-specified dose in the reduction schedule is 10mg once daily. For liver cancer, the starting and step-down doses depend on your weight, so the lowest applicable dose is something your oncologist will confirm for your specific situation. If you cannot tolerate the lowest dose, the conversation shifts to whether continued treatment is feasible or whether a different approach should be considered.

A planned dose interruption — pausing and restarting — is sometimes used alongside or instead of a reduction, depending on the side effect and its severity. It is not the same as a permanent dose reduction, and it is a clinical decision your oncologist makes based on what is happening and how quickly it needs to resolve. Do not pause the drug on your own. Tell your team what you are experiencing and let them determine the safest approach.

Not everyone does, but the majority of people in clinical trials did. Whether you need one depends on how your body responds to the drug and which side effects appear. Some people complete their treatment at the starting dose; others need one reduction; some need two or more. There is no reliable way to predict in advance which group you will fall into, which is why monitoring in the first weeks of treatment is particularly important.

Yes — always. Your team can only make the right dose decision if they know what you are actually experiencing. Many people manage mild side effects quietly to avoid seeming difficult, and this can mean a dose adjustment happens later than it should, after quality of life has already been affected for longer than necessary. Every side effect you report is information that helps your oncologist find the dose that is right for you.